Last reviewed · How we verify
NCT07336225
CMR-Based Prognostic Study in Patients With Cardiac Implantable Electronic Devices
trial testing Cardiac Magnetic Resonance Imaging in Arrhythmias in 1,500 participants. Currently enrolling.
31 December 2035
Quick facts
| Lead sponsor | Chinese Academy of Medical Sciences, Fuwai Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 1,500 |
| Start date | 1 January 2010 |
| Primary completion | 31 December 2035 |
| Estimated completion | 31 December 2040 |
| Sites | 1 location across China |
Drugs / interventions tested
- Cardiac Magnetic Resonance Imaging
Conditions studied
- Arrhythmias — all drugs for Arrhythmias →
Sponsor
Chinese Academy of Medical Sciences, Fuwai Hospital
Who can join
18 and older, any sex, with Arrhythmias. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Cardiac implantable electronic devices (CIEDs) are widely used to treat patients with heart failure, malignant arrhythmias, and other conditions. However, accurately identifying suitable candidates for CIED implantation remains a clinical challenge. Cardiovascular magnetic resonance imaging (CMR) provides a comprehensive assessment of cardiac structure, function, and tissue characteristics, facilitating evaluation of the myocardial substrate for arrhythmias. This study aims to evaluate the prognostic value of multiparametric CMR-derived imaging markers in CIED patients through preoperative CMR examinations. Imaging parameters of interest include structural-functional indices, myocardial strain, late gadolinium enhancement, entropy, and T1 and T2 mapping. Long-term clinical outcomes will be obtained from existing medical records and follow-up. The primary endpoint is sudden cardiac death (SCD) or SCD-equivalent events, defined as SCD, resuscitated cardiac arrest, sustained ventricular tachycardia or ventricular fibrillation, or appropriate ICD therapy. Secondary endpoints include all-cause mortality or heart failure rehospitalization. This study aims to elucidate the role of CMR in assessing CIED treatment indications and long-term risk stratification, thereby helping to optimize CIED implantation decisions.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07336225
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Cardiac Magnetic Resonance Imaging
Trials testing the same drug.
- NCT07103733 — PRIMARY Ancillary Substudy · NA · recruiting
- NCT06916611 — Heart Failure With Preserved Ejection Fraction and Its Cardiac MR Characteristics of Different Subtypes · active not recruiting
- NCT05479669 — Value of Intense Phenotyping in Heart Failure With Preserved Ejection Fraction · recruiting
- NCT04229472 — Characterising the Stable and Dynamic Left Atrial Substrate in Atrial Fibrillation · NA · completed
- NCT04458883 — The Next Leap in Cardiac Magnetic Resonance Imaging:Cycling the Field · NA · recruiting
Other recruiting trials for Arrhythmias
Currently open trials in the same condition.
- NCT06039176 — Human/Machine Interface: What the HeartMate 3 ® Device Tells Us About the Future · recruiting
Other Chinese Academy of Medical Sciences, Fuwai Hospital trials
Trials by the same sponsor.
- NCT07450196 — A Prospective, Multicenter, Observational Study Evaluating Safety and Effectiveness of SAPIEN 3 Transcatheter Aortic Val · not yet recruiting
- NCT07511309 — FFR-Guided Revascularization in Atherosclerotic Renal Artery Stenosis: A Randomized Controlled Trial · NA · not yet recruiting
- NCT07054541 — A Novel Echocardiography-Guided Strategy for Percutateous Closure of Atrial Septal Defect Assisted by PannaWire · Phase 4 · not yet recruiting
- NCT07458672 — TAVR for Aortic Regurgitation Under TTE Guidance · NA · not yet recruiting
- NCT07462325 — Proteomic and Inflammatory Omics Changes With Colchicine Therapy in Coronary Heart Disease · Phase 4 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07336225 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chinese Academy of Medical Sciences, Fuwai Hospital
- Last refreshed: 27 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07336225.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing